RET-Positive Metastatic NSCLC
ESMO 2022 on the Results of the Randomized DICIPLE Phase 3 Trial: Nivo + Ipi 6-Month Treatment vs. Continuation in Advanced NSCLC
By
ESMO 2022 Conference Coverage
FEATURING
Gerard Zalcman
By
ESMO 2022 Conference Coverage
FEATURING
Gerard Zalcman
Login to view comments.
Click here to Login
RET-Positive Metastatic NSCLC